<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although low-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) has been used to treat several <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> like <z:e sem="disease" ids="C0409974" disease_type="Disease or Syndrome" abbrv="">lupus erythematosus</z:e>, <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo>, etc., it has not yet been used to treat patients with <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (PAPS) </plain></SENT>
<SENT sid="1" pm="."><plain>Parallel to clinical follow-up of female patient with a severe form of PAPS, <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL), blood coagulation, and hematological parameters in the peripheral blood have been monitored </plain></SENT>
<SENT sid="2" pm="."><plain>MTX improved <z:mpath ids='MPATH_579'>ulcers</z:mpath>, <z:hpo ids='HP_0000965'>livedo reticularis</z:hpo>, decreased aPL titers, <z:hpo ids='HP_0001894'>increased platelet counts</z:hpo>, and improved blood coagulation parameters (e.g., factor VIII) and was well tolerated </plain></SENT>
<SENT sid="3" pm="."><plain>Low-dose MTX was safe and effective in the presented case with PAPS </plain></SENT>
<SENT sid="4" pm="."><plain>The clinical benefit may be due to the downregulation of increased aPL titers and amelioration of disturbed coagulation parameters </plain></SENT>
</text></document>